KARD

Kardigan Inc

12.67

Oct 23 • 12:43 PM ET -0.07 (-0.57%)

Healthcare Biotechnology USA Small NASD

Peers: CYTK EWTX LXEO TNYA MLYS TECX RCKT BBIO MIST BMY

| Held by: VTI IWM VXF VTWO IWO SCHA IWN GSC VTWG ONEQ

Index	RUT
Market Cap	1.18B
Enterprise Value	600.15M
Income	-
Sales	-
Book/sh	6.59
Cash/sh	6.39
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	210
IPO	Jun 18, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.92
P/C	1.98
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	8.72
Current Ratio	8.72
Debt/Eq	0.02
LT Debt/Eq	0.02
Option/Short	Yes / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-1.01
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	Aug 11 BMO
EPS/Sales Surpr.	-582.66% -

Insider Own	31.67%
Insider Trans	23.45%
Inst Own	61.81%
Inst Trans	159.87%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-8.58%
SMA50	-25.67%
SMA200	-34.28%
Trades

Shs Outstand	93.47M
Shs Float	63.89M
Short Float	6.96%
Short Ratio	8.50
Short Interest	4.45M
52W High	27.00 -53.09%
52W Low	12.23 3.57%
Volatility	8.93% 9.30%
ATR (14)	1.23
RSI (14)	35.28
Beta	-
Rel Volume	1.52
Avg Volume	523.08K
Volume	416,841

Perf Week	-2.79%
Perf Month	-11.97%
Perf Quarter	-40.33%
Perf Half Y	-
Perf YTD	-22.05%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.14
Target Price	39.50
Prev Close	12.74
Price	12.67
Change %	-0.57%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-22-26	Initiated	Robert W. Baird	Outperform	$43
Oct-16-26	Initiated	William Blair	Outperform
Oct-12-26	Initiated	UBS	Buy	$25
Jul-13-26	Initiated	TD Cowen	Buy	$46
Jul-13-26	Initiated	Leerink Partners	Outperform	$37
Jul-13-26	Initiated	JP Morgan	Overweight	$51
Jul-13-26	Initiated	Jefferies	Buy	$40

Sep-30-26 08:00AM	Kardigan Announces Appointment of Kristin Reinke to its Board of Directors (Business Wire)
Sep-02-26 04:05PM	Kardigan to Present at Two September Investor Conferences (Business Wire) +11.84% -5.38%
Aug-11-26 07:11AM	Kardigan: Q2 Earnings Snapshot (Associated Press)
07:00AM	Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates (Business Wire)
Jun-22-26 05:03PM	Kardigan Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (Business Wire)
02:03PM	Loading…
Jun-18-26 02:03PM	Kardigan shares soar after Nasdaq debut (Investing.com)

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HRTG GPE, LLC	10% Owner	Jun 22 '26	Buy	16.00	3,125,000	50,000,000	14,866,868	Jun 24 09:26 PM
BERNS PAUL L	Director	Jun 22 '26	Buy	16.00	1,250,000	20,000,000	15,042,035	Jun 24 04:20 PM
ARCH Venture Partners XIII, LL	Director	Jun 22 '26	Buy	16.00	1,250,000	20,000,000	15,042,035	Jun 24 04:18 PM

Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its "Cardiac Intelligence" platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ.

MBAMr. Tassos Anastasios E. Gianakakos M.Sc.

Ph.D.Dr. Jay Edelberg M.D.

Chief Financial OfficerMs. Brianne Puglisi

Co-founder & Scientific AdvisorDr. Bob McDowell Ph.D.

Co-FounderDr. Leslie A. Leinwand Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KARD

Kardigan Inc

Upgrade your Finviz experience